Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mustang Bio, Inc.    MBIO

MUSTANG BIO, INC.

(MBIO)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2019 10/14/2019 10/15/2019 10/16/2019 10/17/2019 Date
2.87(c) 2.8(c) 2.9(c) 3.08(c) 3.08 Last
153 524 208 568 208 982 296 798 629 988 Volume
-1.03% -2.44% +3.57% +6.21% 0.00% Change
More quotes
Financials (USD)
Sales 2019 -
EBIT 2019 -41,1 M
Net income 2019 -41,4 M
Debt 2019 -
Yield 2019 -
Sales 2020 -
EBIT 2020 -47,7 M
Net income 2020 -48,0 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -2,69x
P/E ratio 2020 -2,78x
Capi. / Sales2019 -
Capi. / Sales2020 -
Capitalization 120 M
More Financials
Company
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies... 
More about the company
Surperformance© ratings of Mustang Bio, Inc.
Trading Rating : Investor Rating : -
More Ratings
Latest news on MUSTANG BIO, INC.
10/10Mustang Bio Announces City of Hope Receives $4.1 Million in Grant Awards for ..
GL
09/30MUSTANG BIO, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Y..
AQ
09/26Mustang Bio to Participate in October 2019 Investor Conferences
GL
09/23Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate S..
GL
09/09Mustang Bio to Present at Scientific Conferences in September 2019
GL
09/03MUSTANG BIO : Adopts CryoStor® Freeze Media and evo® Cold Chain System for Cell ..
PR
08/29Mustang Bio to Present at September 2019 Investor Conferences
GL
08/28MUSTANG BIO : Announces License Agreement with CSL Behring for the Cytegrity Sta..
AQ
08/27Mustang Bio Announces License Agreement with CSL Behring for the Cytegrity&tr..
GL
08/23MUSTANG BIO : and St. Jude Children's Research Hospital announce MB-107 lentivir..
AQ
08/22MUSTANG BIO : and St. Jude Children's Research Hospital announce MB-107 lentivir..
AQ
08/13Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Ther..
GL
08/12MUSTANG BIO : Reports Second Quarter 2019 Financial Results and Recent Corporate..
AQ
08/12Mustang Bio to Present at 11th Annual Bioprocessing Summit
GL
08/09MUSTANG BIO, INC. : Results of Operations and Financial Condition, Financial Sta..
AQ
More news
News in other languages on MUSTANG BIO, INC.

- No features available -

More news
Analyst Recommendations on MUSTANG BIO, INC.
More recommendations
Sector news : Bio Therapeutic Drugs
04:01pProspects for a Brexit Deal Cheer Businesses, but Big Questions Remain
DJ
08:29aGLOBAL MARKETS LIVE : Nestlé, Netflix, Huawei, General Motors…
10/16INCYTE : Says Phase 3 REACH2 Trial Meets Endpoint
DJ
10/15New Gilead Sciences CFO Expected to Pursue More Deals to Expand Portfolio
DJ
10/15GILEAD SCIENCES : Names Andrew Dickinson Chief Financial Officer
DJ
More sector news : Bio Therapeutic Drugs
Chart MUSTANG BIO, INC.
Duration : Period :
Mustang Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MUSTANG BIO, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 10,67  $
Last Close Price 3,08  $
Spread / Highest target 484%
Spread / Average Target 246%
Spread / Lowest Target 127%
EPS Revisions
Managers
NameTitle
Manuel Litchman President, Chief Executive Officer & Director
Michael Sean Weiss Executive Chairman
Brian Achenbach Vice President-Finance & Controller
Knut Niss Chief Technology Officer
Martina A. Sersch Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MUSTANG BIO, INC.4.76%120
GILEAD SCIENCES4.48%82 763
VERTEX PHARMACEUTICALS6.29%45 261
REGENERON PHARMACEUTICALS-19.84%32 761
WUXI APPTEC CO., LTD.65.00%20 165
GENMAB30.26%13 396